Shares Outstanding Shares Outstanding n/a Close	25.95M
Shares Change (YoY) Shares Change (YoY) n/a Close	45.58%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	0.71%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	4.19%
Shares Floating Shares Floating n/a Close	8.31M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	1,771
FTD / Avg. Volume FTD / Avg. Volume n/a Close	1.83%

Short Selling Information

The latest short interest is 2.55M, so 9.83% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	2.55M
Short % of Shares Out Short % of Shares Out n/a Close	9.83%
Short % of Float Short % of Float n/a Close	24.77%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	40.97

Valuation Ratios

The PE ratio is -4 and the forward PE ratio is -2.61. Cartesian Therapeutics's PEG ratio is 0.04.

PE Ratio PE Ratio n/a Close	-4
Forward PE Forward PE n/a Close	-2.61
PS Ratio PS Ratio n/a Close	7.95
Forward PS Forward PS n/a Close	2.4
PB Ratio PB Ratio n/a Close	-45.49
P/FCF Ratio P/FCF Ratio n/a Close	-9.44
PEG Ratio PEG Ratio n/a Close	0.04

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Cartesian Therapeutics.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 9.43, with a Debt / Equity ratio of -2.06.

Current Ratio Current Ratio n/a Close	9.43
Quick Ratio Quick Ratio n/a Close	9.43
Debt / Equity Debt / Equity n/a Close	-2.06
Debt / EBITDA Debt / EBITDA n/a Close	-0.18
Debt / FCF Debt / FCF n/a Close	-0.43
Interest Coverage Interest Coverage n/a Close	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$589,590.91
Profits Per Employee Profits Per Employee n/a Close	$-1,173,090.91
Employee Count Employee Count n/a Close	66
Asset Turnover Asset Turnover n/a Close	0.09
Inventory Turnover Inventory Turnover n/a Close	n/a

Taxes

Income Tax Income Tax n/a Close	287K
Effective Tax Rate Effective Tax Rate n/a Close	-0.37%

Stock Price Statistics

The stock price has increased by -62% in the last 52 weeks. The beta is 0.32, so Cartesian Therapeutics's price volatility has been higher than the market average.

Beta Beta n/a Close	0.32
52-Week Price Change 52-Week Price Change n/a Close	-62%
50-Day Moving Average 50-Day Moving Average n/a Close	10.63
200-Day Moving Average 200-Day Moving Average n/a Close	16.45
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	50.37
Average Volume (20 Days) Average Volume (20 Days) n/a Close	96,992

Income Statement

In the last 12 months, Cartesian Therapeutics had revenue of 38.91M and earned -77.42M in profits. Earnings per share was -0.5.

Revenue Revenue n/a Close	38.91M
Gross Profit Gross Profit n/a Close	38.91M
Operating Income Operating Income n/a Close	-43.9M
Net Income Net Income n/a Close	-77.42M
EBITDA EBITDA n/a Close	-77.14M
EBIT EBIT n/a Close	-77.14M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-0.5

Full Income Statement

Balance Sheet

The company has 212.61M in cash and 13.98M in debt, giving a net cash position of 198.63M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	212.61M
Total Debt Total Debt n/a Close	13.98M
Net Cash Net Cash n/a Close	198.63M
Retained Earnings Retained Earnings n/a Close	-692.07M
Total Assets Total Assets n/a Close	409.13M
Working Capital Working Capital n/a Close	170.12M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -23.67M and capital expenditures -9.09M, giving a free cash flow of -32.77M.

Operating Cash Flow Operating Cash Flow n/a Close	-23.67M
Capital Expenditures Capital Expenditures n/a Close	-9.09M
Free Cash Flow Free Cash Flow n/a Close	-32.77M
FCF Per Share FCF Per Share n/a Close	-1.9

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -112.81% and -198.97%.

Gross Margin Gross Margin n/a Close	100%
Operating Margin Operating Margin n/a Close	-112.81%
Pretax Margin Pretax Margin n/a Close	-198.23%
Profit Margin Profit Margin n/a Close	-198.97%
EBITDA Margin EBITDA Margin n/a Close	-198.23%
EBIT Margin EBIT Margin n/a Close	-112.81%
FCF Margin FCF Margin n/a Close	-84.21%

Dividends & Yields

RNAC does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for RNAC is $41, which is 295.4% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$41
Price Target Difference Price Target Difference n/a Close	295.4%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	6

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Apr 5, 2024. It was a backward split with a ratio of 1:30.

Last Split Date Last Split Date n/a Close	Apr 5, 2024
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:30

Scores

Altman Z-Score Altman Z-Score n/a Close	-1.83
Piotroski F-Score Piotroski F-Score n/a Close	4